Skip to main content
Rates starting at

$XXX USD

Select your dates at Cambria Hotel Boston, Downtown-South Boston

Your Selected Dates 1 night

  • Thursday
  • 1 night
  • Sunday
Submit dates

Reservation: 617-752-6681

Check-in: 3:00 PM Check-out: 11:00 AM

Pets allowed: No

Book Direct Benefits
  • Members Save 7%
  • Lowest price guaranteed
  • Earn Choice Privileges points on your stay

2nd TGF-β for Immuno-Oncology Drug Development Summit

Other

About This Event

From Cell Signaling to the Tumor Microenvironment, Exploit TGF-β’s Role in IO to Harness a Clinically Relevant, Safe & Efficacious Therapeutics\ \ It is clear the world of TGF-β contains vast potential and excitement, in the past year alone we have seen great advances, clinical setbacks, and novel insights into the role of TGF-β.\ \ Over the last 12 months, we have seen so many highs and lows, including clinical updates from large pharma such as Novartis, Oncotelic Therapeutics, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate.\ \ With the vast volume of candidates moving into the clinic, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression.\ \ Tailored with 31+ senior leaders, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert, this meeting will provide you with the must-know takeaways from biology to translational modeling, from biomarkers to clinical trial design across 3 days.\ \ What’s New in 2022?\ - Improve our core understanding of TGF-β function and biology\ - With insights from Genentech, Leucid Bio, NIH and more, this summit will provide a comprehensive guide on the basic science of TGF-β\ - Better mechanistic knowledge of TGF-β regulators\ - Leverage insights into the interplay of cells in the tumor landscape and explore the methods for targeting TGF-β with Mestag Therapeutics, Takeda, and Kalivir Immunotherapeutics\ - Gain novel insights into TGF-β and therapeutic interactions through advanced modeling\ - Revolutionize preclinical insights with a new TGF-β reporter mouse f